---
title: "Tozorakimab shows ~30% reduction in COPD exacerbations in Phase 3 trials"
id: "stat-news-0-stat-astrazeneca-s-experimental-copd-treatment-posts-strong-results-in-late"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-astrazeneca-s-experimental-copd-treatment-posts-strong-results-in-late"
content_type: "clinical_feed_article"
specialty: "Pulmonology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon/?utm_campaign=rss"
published_at: "2026-09-08T11:45:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Tozorakimab shows ~30% reduction in COPD exacerbations in Phase 3 trials
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-astrazeneca-s-experimental-copd-treatment-posts-strong-results-in-late
- **Specialty:** [Pulmonology](https://medichelpline.com/clinical-feed/pulmonology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon/?utm_campaign=rss)
- **Published At:** 2026-09-08T11:45:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- AstraZeneca’s investigational monoclonal antibody **tozorakimab** produced a roughly **30%** reduction in COPD exacerbations across all patients over one year in two Phase 3 trials, according to data presented at the European Respiratory Society annual meeting and published in the **New England Journal of Medicine**. - The trials targeted exacerbations, defined as sudden worsenings of COPD requiring medical care, including severe cough or breathlessness. - Results position tozorakimab as a potential new treatment option for the large and underserved population with **COPD**, the third-leading cause of death worldwide. - The studies included participants who were not eligible for other recently approved COPD therapies; the observed benefit in this subgroup could allow AstraZeneca to capture a substantial segment of the market. - Positive Phase 3 data represent a notable commercial and scientific win for AstraZeneca following a period that included high-profile clinical trial disappointments. - Analysts and the company have estimated that, if approved, tozorakimab could generate multi-billion-dollar annual sales by extending into COPD and other respiratory conditions such as asthma. - The data were reported by STAT News (Andrew Joseph) on Sept. 8, 2026; additional granular trial methodology, safety, and subgroup details were not reported in the source beyond the published presentation and NEJM publication. - The verdict on regulatory approval, labeling, and real-world adoption will depend on further review of the full trial datasets and regulatory assessments; those processes and timelines were not detailed in the source.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon/?utm_campaign=rss) [patients](https://www.statnews.com/topic/patients/) [Cancer](https://www.statnews.com/topic/cancer/) [cardiology](https://www.statnews.com/topic/cardiology/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Pharma](https://www.statnews.com/category/pharma/) # AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies ## Approval could deliver patients a new options and produce a windfall for the pharma company * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/09/C0400970-Smoker_s_lungs_and_emphysema_3D_CT_scan-645x645.jpg) An image of the lungs of a patient with COPDK H FUNG / SCIENCE PHOTO LIBRARY ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) Sept. 8, 2026 Europe Correspondent ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") andrew.joseph@statnews.com Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. In a pair of late-stage trials, a drug from AstraZeneca reduced the dangerous flare-ups that drive the worsening of COPD, positioning it as a potential new option for the vast numbers of patients with the debilitating lung condition, according to data released Tuesday. Results from the Phase 3 trials of the drug, called tozorakimab, also amount to a re-assuring victory for AstraZeneca, which is known for its metronomic success in trials but has seen some notable misses in recent months, most dramatically with a [heart disease drug](https://www.statnews.com/2026/08/28/astrazeneca-ionis-wainua-eplontersen-attr-cm-study-failure-bridgebio-alnylam/). Analysts and the company have projected that “tozo,” as the injectable drug is dubbed, could reap billions in annual sales if approved, both in COPD — which, as the third-leading cause of death globally, remains greatly underserved — and in other conditions including asthma. Advertisement In the trials, tozo reduced COPD exacerbations — any sudden worsening of the disease requiring medical care, whether a severe cough or breathlessness — by about 30% across all patients over a year, according to data presented at the European Respiratory Society’s annual conference in Barcelona and [published](http://www.nejm.org/doi/full/10.1056/NEJMoa2606998) in the New England Journal of Medicine. That finding makes tozo competitive with other COPD treatments that have reached patients in recent years, but notably, the tozo trials included participants not eligible for the other new drugs. The benefits seen in those patients could give AstraZeneca a large segment of the market to itself. [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [chronic disease](https://www.statnews.com/topic/chronic-disease/), [drug development](https://www.statnews.com/topic/drug-development/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") 2. Europe Correspondent 1. [](https://x.com/DrewQJoseph "X") 2. Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/09/Solano-Family-80x80.jpg) [A breakthrough pancreatic cancer drug won approval. They still struggle to access it](https://www.statnews.com/2026/09/08/pancreatic-cancer-patients-caught-beween-fda-drug-approval-insurance-coverage/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/01/heart-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation](https://www.statnews.com/2026/09/07/novo-nordisk-heart-studies-inflammation-ziltivekimab/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/09/Bogalusa-3-80x80.jpg) [Hospitals pursue deals to ensure survival as Trump’s Medicaid cuts loom](https://www.statnews.com/2026/09/08/rural-hospital-mergers-medicaid-cuts-part-3-unraveled-series/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/09/AdobeStock_744812776-80x80.jpeg) [I’m a fat medical student. I refuse to let myself be shamed for it](https://www.statnews.com/2026/09/08/fat-medical-student-inclusivity-advocacy-health-at-any-size-physician/) 5. ![](https://www.statnews.com/wp-content/uploads/2018/10/STAT_Novartis01-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Neuromuscular drug from Novartis fails in key study, adding to pressure on company](https://www.statnews.com/2026/09/08/novartis-del-desiran-myotonic-dystrophy-harbor-trial-failure-neuromuscular/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_1240429246-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [NIH proposal to cap research grants draws mixed reception, agency says](https://www.statnews.com/2026/09/01/nih-grant-cap-proposal-researcher-feedback/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/09/Lindsay_Clancy_Trial_8_1_1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Lindsay Clancy case exposes dangers of fragmented U.S. health system, experts say](https://www.statnews.com/2026/09/04/lindsay-clancy-health-care-silos-postpartum-care-failures/) 3. ![](https://www.statnews.com/wp-content/uploads/2018/10/STAT_Novartis02-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novartis’ experimental cardiovascular drug fails a pivotal study](https://www.statnews.com/2026/09/04/novartis-therapy-pelacarsen-fails-cardiovascular-trial/) 4. ![](https://www.statnews.com/wp-content/uploads/2024/05/s3___bgmp-arc_arc-feeds_generic-photos_to-arc_Wiggs-_Bedford_2-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial](https://www.statnews.com/2026/09/02/ultragenyx-drug-angelman-syndrome-clinical-trial/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/09/AP23227774736501-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Recipients of gene-edited pig kidneys successfully receive human organs](https://www.statnews.com/2026/09/03/recipients-of-gene-edited-pig-kidneys-receive-human-organs/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Morning Rounds Morning Rounds September 8, 2026 ### [ An administrative gap delays access to new pancreatic cancer treatment ](https://www.statnews.com/2026/09/08/health-news-administrative-gap-delays-access-to-revmed-pancreatic-cancer-drug/) By [Theresa Gaffney](https://www.statnews.com/staff/theresa-gaffney/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech September 8, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Inhibrx claims first win for long-sought immunotherapy target ](https://www.statnews.com/2026/09/08/inhibrx-inbrx-106-ox40-immunotherapy-head-and-neck-cancer-hpv-positive/) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech September 8, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Roivant lung disease drug hits mid-stage study goals ](https://www.statnews.com/2026/09/08/roivant-mosliciguat-pulmonary-hypertension-interstitial-lung-disease-results/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Health Health September 8, 2026 ### [ Reynolds is selling fruity new vapes unauthorized by FDA ](https://www.statnews.com/2026/09/08/fda-guidance-reynolds-selling-fruity-new-vapes-unauthorized/) By [Sarah Todd](https://www.statnews.com/staff/sarah-todd/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Health Health September 8, 2026 ### [ A breakthrough pancreatic cancer drug won approval. They still struggle to access it ](https://www.statnews.com/2026/09/08/pancreatic-cancer-patients-caught-beween-fda-drug-approval-insurance-coverage/) By [Angus Chen](https://www.statnews.com/staff/angus-chen/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Abivax has still not been acquired. What’s going on? ](https://www.statnews.com/2026/09/03/abivax-acquisition-target-replimune-fda/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Lindsay Clancy case exposes dangers of fragmented U.S. health system, experts say ](https://www.statnews.com/2026/09/04/lindsay-clancy-health-care-silos-postpartum-care-failures/) By [Tara Bannow](https://www.statnews.com/staff/tara-bannow/) 3. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: ADA review of members’ expulsion denies group censored opinions, called in police ](https://www.statnews.com/2026/09/01/ada-members-review-june-expulsion-denies-censoring-opinions-calling-new-orleans-police/) By [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) 4. ### [ Doctors groups release vaccination guidelines ahead of respiratory illness season ](https://www.statnews.com/2026/09/02/vaccine-integrity-project-fall-winter-guidelines-rsv-covid-flu-shots/) By [Helen Branswell](https://www.statnews.com/staff/helen-branswell/) 5. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: The ERs that can turn patients away — and are reaping millions ](https://www.statnews.com/2026/06/29/nutex-health-micro-hospitals-er-loophole-idr-profits/) By [Tara Bannow](https://www.statnews.com/staff/tara-bannow/) Share options * [ X ](https://twitter.com/intent/tweet?url=https://www.statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon/&via=statnews&text=AstraZeneca%E2%80%99s%20experimental%20COPD%20treatment%20posts%20strong%20results%20in%20late-stage%20studies "Share on X") * [ Bluesky ](https://bsky.app/intent/compose?text=AstraZeneca%E2%80%99s%20experimental%20COPD%20treatment%20posts%20strong%20results%20in%20late-stage%20studies%20https://www.statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon/%20via%20@statnews.com "Share on Bluesky") * [ LinkedIn ](https://www.linkedin.com/shareArticle?url=https://www.statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon/&mini=true&source=STAT "Linkedin") * [ Facebook ](https://www.facebook.com/sharer/sharer.php?u=https://www.statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon/ "Facebook") * [ Doximity ](https://www.doximity.com/inbox/conversations/new_message?url=https%3A%2F%2Fwww.statnews.com%2F2026%2F09%2F08%2Fastrazeneca-
## Related Clinical Research

- [Medicare expands ACCESS pilot to cover more chronic conditions and lists 39 providers](https://medichelpline.com/clinical-feed/stat-news-1-stat-medicare-to-expand-its-pilot-that-pays-for-technology-to-manage-chronic.md)
- [FDA approves Isembyld for spinal muscular atrophy — first therapy targeting muscle loss](https://medichelpline.com/clinical-feed/stat-news-0-stat-scholar-rock-wins-fda-approval-for-first-drug-to-target-sma-muscle-loss.md)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [Keto Diet Shows Superior Metabolic Benefits Over Mediterranean and Low-Fat Diets](https://medichelpline.com/clinical-feed/medical-news-today-1-keto-diet-may-have-metabolic-advantages-over-mediterranean-low-fat-diets.md)

## Navigation
- [← Back to Pulmonology Feed](https://medichelpline.com/clinical-feed/pulmonology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.